nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—CYP1B1—ovarian cancer	0.166	0.448	CbGaD
Erlotinib—EGFR—ovarian cancer	0.157	0.423	CbGaD
Erlotinib—NR1I2—Paclitaxel—ovarian cancer	0.0684	0.188	CbGbCtD
Erlotinib—EGFR—Docetaxel—ovarian cancer	0.0543	0.149	CbGbCtD
Erlotinib—NR1I2—Docetaxel—ovarian cancer	0.0494	0.136	CbGbCtD
Erlotinib—ABCB1—ovarian cancer	0.0477	0.129	CbGaD
Erlotinib—CYP1B1—Paclitaxel—ovarian cancer	0.0261	0.0718	CbGbCtD
Erlotinib—ABCG2—Topotecan—ovarian cancer	0.0251	0.0689	CbGbCtD
Erlotinib—CYP1B1—Docetaxel—ovarian cancer	0.0189	0.0519	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—ovarian cancer	0.0141	0.0387	CbGbCtD
Erlotinib—ABCG2—Paclitaxel—ovarian cancer	0.0124	0.0341	CbGbCtD
Erlotinib—ABCG2—Carboplatin—ovarian cancer	0.0117	0.0321	CbGbCtD
Erlotinib—ABCB1—Topotecan—ovarian cancer	0.00903	0.0249	CbGbCtD
Erlotinib—ABCG2—Docetaxel—ovarian cancer	0.00897	0.0247	CbGbCtD
Erlotinib—CYP3A5—Paclitaxel—ovarian cancer	0.00687	0.0189	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—ovarian cancer	0.00668	0.0184	CbGbCtD
Erlotinib—CYP2C8—Paclitaxel—ovarian cancer	0.00661	0.0182	CbGbCtD
Erlotinib—ABCB1—Vinorelbine—ovarian cancer	0.00637	0.0175	CbGbCtD
Erlotinib—CYP2D6—Vinorelbine—ovarian cancer	0.006	0.0165	CbGbCtD
Erlotinib—CYP3A4—Topotecan—ovarian cancer	0.00541	0.0149	CbGbCtD
Erlotinib—CYP3A5—Docetaxel—ovarian cancer	0.00497	0.0137	CbGbCtD
Erlotinib—ABCB1—Paclitaxel—ovarian cancer	0.00447	0.0123	CbGbCtD
Erlotinib—CYP3A4—Vinorelbine—ovarian cancer	0.00381	0.0105	CbGbCtD
Erlotinib—ABCB1—Docetaxel—ovarian cancer	0.00323	0.0089	CbGbCtD
Erlotinib—CYP3A4—Paclitaxel—ovarian cancer	0.00268	0.00737	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—ovarian cancer	0.00241	0.00663	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—ovarian cancer	0.00227	0.00625	CbGbCtD
Erlotinib—CYP3A4—Docetaxel—ovarian cancer	0.00194	0.00533	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—ovarian cancer	0.00144	0.00397	CbGbCtD
Erlotinib—Gefitinib—CHEK2—ovarian cancer	0.0013	0.41	CrCbGaD
Erlotinib—HIPK4—gonad—ovarian cancer	0.000982	0.0145	CbGeAlD
Erlotinib—HIPK4—female reproductive system—ovarian cancer	0.000877	0.013	CbGeAlD
Erlotinib—LTK—female reproductive system—ovarian cancer	0.000867	0.0128	CbGeAlD
Erlotinib—TNK1—uterine cervix—ovarian cancer	0.00085	0.0126	CbGeAlD
Erlotinib—PIP4K2C—myometrium—ovarian cancer	0.000847	0.0125	CbGeAlD
Erlotinib—AURKC—gonad—ovarian cancer	0.000838	0.0124	CbGeAlD
Erlotinib—TNK1—decidua—ovarian cancer	0.000809	0.012	CbGeAlD
Erlotinib—ULK3—myometrium—ovarian cancer	0.000809	0.012	CbGeAlD
Erlotinib—EPHA6—gonad—ovarian cancer	0.000776	0.0115	CbGeAlD
Erlotinib—TNK1—endometrium—ovarian cancer	0.000768	0.0114	CbGeAlD
Erlotinib—MKNK1—myometrium—ovarian cancer	0.000761	0.0113	CbGeAlD
Erlotinib—AURKC—female reproductive system—ovarian cancer	0.000749	0.0111	CbGeAlD
Erlotinib—SLK—myometrium—ovarian cancer	0.000721	0.0107	CbGeAlD
Erlotinib—TNK1—uterus—ovarian cancer	0.000708	0.0105	CbGeAlD
Erlotinib—HIPK4—testis—ovarian cancer	0.000708	0.0105	CbGeAlD
Erlotinib—LTK—testis—ovarian cancer	0.0007	0.0104	CbGeAlD
Erlotinib—JAK3—female reproductive system—ovarian cancer	0.000693	0.0103	CbGeAlD
Erlotinib—EPHA6—female reproductive system—ovarian cancer	0.000693	0.0103	CbGeAlD
Erlotinib—EGFR—uterine cervix—ovarian cancer	0.00068	0.0101	CbGeAlD
Erlotinib—PIP4K2C—uterine cervix—ovarian cancer	0.000659	0.00977	CbGeAlD
Erlotinib—Vandetanib—VEGFA—ovarian cancer	0.000649	0.204	CrCbGaD
Erlotinib—JAK3—female gonad—ovarian cancer	0.000631	0.00934	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—ovarian cancer	0.00063	0.00933	CbGeAlD
Erlotinib—ULK3—uterine cervix—ovarian cancer	0.00063	0.00932	CbGeAlD
Erlotinib—PIP4K2C—decidua—ovarian cancer	0.000628	0.0093	CbGeAlD
Erlotinib—STK10—myometrium—ovarian cancer	0.000627	0.00929	CbGeAlD
Erlotinib—FLT3—gonad—ovarian cancer	0.000612	0.00907	CbGeAlD
Erlotinib—AURKC—testis—ovarian cancer	0.000604	0.00895	CbGeAlD
Erlotinib—ULK3—decidua—ovarian cancer	0.0006	0.00888	CbGeAlD
Erlotinib—PIP4K2C—endometrium—ovarian cancer	0.000596	0.00883	CbGeAlD
Erlotinib—MKNK1—uterine cervix—ovarian cancer	0.000593	0.00878	CbGeAlD
Erlotinib—TNK1—female gonad—ovarian cancer	0.000579	0.00858	CbGeAlD
Erlotinib—TNK1—vagina—ovarian cancer	0.000576	0.00853	CbGeAlD
Erlotinib—ULK3—endometrium—ovarian cancer	0.000569	0.00843	CbGeAlD
Erlotinib—EGFR—uterus—ovarian cancer	0.000567	0.0084	CbGeAlD
Erlotinib—MKNK1—decidua—ovarian cancer	0.000565	0.00836	CbGeAlD
Erlotinib—SLK—uterine cervix—ovarian cancer	0.000561	0.00831	CbGeAlD
Erlotinib—MAP2K5—myometrium—ovarian cancer	0.00056	0.00829	CbGeAlD
Erlotinib—JAK3—testis—ovarian cancer	0.00056	0.00829	CbGeAlD
Erlotinib—EPHA6—testis—ovarian cancer	0.00056	0.00829	CbGeAlD
Erlotinib—PIP4K2C—gonad—ovarian cancer	0.000553	0.00819	CbGeAlD
Erlotinib—Vandetanib—EGFR—ovarian cancer	0.000547	0.172	CrCbGaD
Erlotinib—FLT3—female reproductive system—ovarian cancer	0.000547	0.0081	CbGeAlD
Erlotinib—MKNK1—endometrium—ovarian cancer	0.000536	0.00794	CbGeAlD
Erlotinib—SLK—decidua—ovarian cancer	0.000535	0.00792	CbGeAlD
Erlotinib—ULK3—gonad—ovarian cancer	0.000528	0.00782	CbGeAlD
Erlotinib—ULK3—uterus—ovarian cancer	0.000525	0.00777	CbGeAlD
Erlotinib—Gefitinib—EGFR—ovarian cancer	0.00052	0.164	CrCbGaD
Erlotinib—FLT3—bone marrow—ovarian cancer	0.000516	0.00765	CbGeAlD
Erlotinib—TNK1—testis—ovarian cancer	0.000514	0.00761	CbGeAlD
Erlotinib—MAP3K19—testis—ovarian cancer	0.000509	0.00753	CbGeAlD
Erlotinib—SLK—endometrium—ovarian cancer	0.000508	0.00752	CbGeAlD
Erlotinib—LTK—lymph node—ovarian cancer	0.000507	0.00751	CbGeAlD
Erlotinib—FLT3—female gonad—ovarian cancer	0.000498	0.00737	CbGeAlD
Erlotinib—MKNK1—gonad—ovarian cancer	0.000497	0.00736	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—ovarian cancer	0.000494	0.00732	CbGeAlD
Erlotinib—STK10—uterine cervix—ovarian cancer	0.000488	0.00723	CbGeAlD
Erlotinib—ABL2—female gonad—ovarian cancer	0.000475	0.00704	CbGeAlD
Erlotinib—ABL2—vagina—ovarian cancer	0.000472	0.00699	CbGeAlD
Erlotinib—ULK3—female reproductive system—ovarian cancer	0.000472	0.00699	CbGeAlD
Erlotinib—SLK—uterus—ovarian cancer	0.000468	0.00693	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—ovarian cancer	0.000466	0.00691	CbGeAlD
Erlotinib—STK10—decidua—ovarian cancer	0.000465	0.00689	CbGeAlD
Erlotinib—EGFR—female gonad—ovarian cancer	0.000464	0.00687	CbGeAlD
Erlotinib—PIP4K2C—female gonad—ovarian cancer	0.00045	0.00666	CbGeAlD
Erlotinib—PIP4K2C—vagina—ovarian cancer	0.000447	0.00662	CbGeAlD
Erlotinib—ULK3—bone marrow—ovarian cancer	0.000445	0.0066	CbGeAlD
Erlotinib—MKNK1—female reproductive system—ovarian cancer	0.000444	0.00658	CbGeAlD
Erlotinib—FLT3—testis—ovarian cancer	0.000441	0.00654	CbGeAlD
Erlotinib—AURKC—lymph node—ovarian cancer	0.000438	0.00649	CbGeAlD
Erlotinib—MAP2K5—uterine cervix—ovarian cancer	0.000436	0.00645	CbGeAlD
Erlotinib—ABL1—myometrium—ovarian cancer	0.000432	0.0064	CbGeAlD
Erlotinib—ULK3—female gonad—ovarian cancer	0.000429	0.00636	CbGeAlD
Erlotinib—ULK3—vagina—ovarian cancer	0.000427	0.00632	CbGeAlD
Erlotinib—ABL2—testis—ovarian cancer	0.000421	0.00624	CbGeAlD
Erlotinib—MKNK1—bone marrow—ovarian cancer	0.000419	0.00621	CbGeAlD
Erlotinib—ABL1—embryo—ovarian cancer	0.000416	0.00615	CbGeAlD
Erlotinib—MAP2K5—decidua—ovarian cancer	0.000415	0.00615	CbGeAlD
Erlotinib—EGFR—testis—ovarian cancer	0.000411	0.00609	CbGeAlD
Erlotinib—STK10—gonad—ovarian cancer	0.000409	0.00606	CbGeAlD
Erlotinib—STK10—uterus—ovarian cancer	0.000407	0.00602	CbGeAlD
Erlotinib—JAK3—lymph node—ovarian cancer	0.000406	0.00601	CbGeAlD
Erlotinib—MKNK1—female gonad—ovarian cancer	0.000404	0.00598	CbGeAlD
Erlotinib—MKNK1—vagina—ovarian cancer	0.000402	0.00595	CbGeAlD
Erlotinib—PIP4K2C—testis—ovarian cancer	0.000399	0.0059	CbGeAlD
Erlotinib—SLK—bone marrow—ovarian cancer	0.000397	0.00588	CbGeAlD
Erlotinib—MAP2K5—endometrium—ovarian cancer	0.000394	0.00584	CbGeAlD
Erlotinib—SLK—female gonad—ovarian cancer	0.000383	0.00567	CbGeAlD
Erlotinib—ULK3—testis—ovarian cancer	0.000381	0.00564	CbGeAlD
Erlotinib—SLK—vagina—ovarian cancer	0.00038	0.00563	CbGeAlD
Erlotinib—TNK1—lymph node—ovarian cancer	0.000372	0.00551	CbGeAlD
Erlotinib—STK10—female reproductive system—ovarian cancer	0.000366	0.00541	CbGeAlD
Erlotinib—MKNK1—testis—ovarian cancer	0.000358	0.00531	CbGeAlD
Erlotinib—STK10—bone marrow—ovarian cancer	0.000345	0.00511	CbGeAlD
Erlotinib—SLK—testis—ovarian cancer	0.000339	0.00503	CbGeAlD
Erlotinib—ABL1—uterine cervix—ovarian cancer	0.000336	0.00498	CbGeAlD
Erlotinib—STK10—female gonad—ovarian cancer	0.000333	0.00493	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000332	0.173	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000332	0.173	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000332	0.173	CbGdCrCtD
Erlotinib—STK10—vagina—ovarian cancer	0.000331	0.0049	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—ovarian cancer	0.000327	0.00484	CbGeAlD
Erlotinib—SLCO2B1—decidua—ovarian cancer	0.000323	0.00478	CbGeAlD
Erlotinib—ABL1—decidua—ovarian cancer	0.00032	0.00474	CbGeAlD
Erlotinib—ORM1—endometrium—ovarian cancer	0.00032	0.00474	CbGeAlD
Erlotinib—FLT3—lymph node—ovarian cancer	0.00032	0.00474	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000307	0.16	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000307	0.16	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000307	0.16	CbGdCrCtD
Erlotinib—ABL2—lymph node—ovarian cancer	0.000305	0.00452	CbGeAlD
Erlotinib—ABL1—endometrium—ovarian cancer	0.000304	0.0045	CbGeAlD
Erlotinib—EGFR—lymph node—ovarian cancer	0.000298	0.00442	CbGeAlD
Erlotinib—MAP2K5—female gonad—ovarian cancer	0.000297	0.0044	CbGeAlD
Erlotinib—MAP2K5—vagina—ovarian cancer	0.000295	0.00437	CbGeAlD
Erlotinib—STK10—testis—ovarian cancer	0.000295	0.00437	CbGeAlD
Erlotinib—PIP4K2C—lymph node—ovarian cancer	0.000289	0.00428	CbGeAlD
Erlotinib—SLCO2B1—uterus—ovarian cancer	0.000283	0.00419	CbGeAlD
Erlotinib—ABL1—gonad—ovarian cancer	0.000282	0.00418	CbGeAlD
Erlotinib—ABL1—uterus—ovarian cancer	0.00028	0.00415	CbGeAlD
Erlotinib—ULK3—lymph node—ovarian cancer	0.000276	0.00409	CbGeAlD
Erlotinib—ABCG2—myometrium—ovarian cancer	0.000272	0.00403	CbGeAlD
Erlotinib—CYP1B1—decidua—ovarian cancer	0.000271	0.00402	CbGeAlD
Erlotinib—ORM1—female reproductive system—ovarian cancer	0.000265	0.00393	CbGeAlD
Erlotinib—MAP2K5—testis—ovarian cancer	0.000264	0.0039	CbGeAlD
Erlotinib—MKNK1—lymph node—ovarian cancer	0.00026	0.00385	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—ovarian cancer	0.000254	0.00376	CbGeAlD
Erlotinib—ABL1—female reproductive system—ovarian cancer	0.000252	0.00373	CbGeAlD
Erlotinib—ORM1—bone marrow—ovarian cancer	0.00025	0.00371	CbGeAlD
Erlotinib—SLK—lymph node—ovarian cancer	0.000246	0.00364	CbGeAlD
Erlotinib—CYP1B1—gonad—ovarian cancer	0.000239	0.00354	CbGeAlD
Erlotinib—ABL1—bone marrow—ovarian cancer	0.000238	0.00352	CbGeAlD
Erlotinib—CYP1B1—uterus—ovarian cancer	0.000237	0.00351	CbGeAlD
Erlotinib—SLCO2B1—female gonad—ovarian cancer	0.000231	0.00342	CbGeAlD
Erlotinib—ABL1—female gonad—ovarian cancer	0.000229	0.00339	CbGeAlD
Erlotinib—ABL1—vagina—ovarian cancer	0.000228	0.00337	CbGeAlD
Erlotinib—STK10—lymph node—ovarian cancer	0.000214	0.00317	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—ovarian cancer	0.000213	0.00316	CbGeAlD
Erlotinib—ABCG2—uterine cervix—ovarian cancer	0.000212	0.00314	CbGeAlD
Erlotinib—SLCO2B1—testis—ovarian cancer	0.000205	0.00304	CbGeAlD
Erlotinib—ABL1—testis—ovarian cancer	0.000203	0.00301	CbGeAlD
Erlotinib—CYP1A1—epithelium—ovarian cancer	0.000203	0.00301	CbGeAlD
Erlotinib—ABCG2—decidua—ovarian cancer	0.000202	0.00299	CbGeAlD
Erlotinib—CYP1A1—uterine cervix—ovarian cancer	0.000201	0.00298	CbGeAlD
Erlotinib—CYP2C8—endometrium—ovarian cancer	0.000197	0.00292	CbGeAlD
Erlotinib—CYP3A5—uterine cervix—ovarian cancer	0.000197	0.00291	CbGeAlD
Erlotinib—CYP1B1—female gonad—ovarian cancer	0.000194	0.00287	CbGeAlD
Erlotinib—ABCG2—endometrium—ovarian cancer	0.000192	0.00284	CbGeAlD
Erlotinib—MAP2K5—lymph node—ovarian cancer	0.000191	0.00283	CbGeAlD
Erlotinib—ALB—testis—ovarian cancer	0.000188	0.00278	CbGeAlD
Erlotinib—ABCG2—uterus—ovarian cancer	0.000177	0.00262	CbGeAlD
Erlotinib—CYP1B1—testis—ovarian cancer	0.000172	0.00255	CbGeAlD
Erlotinib—CYP1A1—uterus—ovarian cancer	0.000168	0.00248	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—ovarian cancer	0.000163	0.00242	CbGeAlD
Erlotinib—Gefitinib—ABCB1—ovarian cancer	0.000158	0.0498	CrCbGaD
Erlotinib—ORM1—lymph node—ovarian cancer	0.000155	0.0023	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—ovarian cancer	0.000151	0.00223	CbGeAlD
Erlotinib—ABCG2—bone marrow—ovarian cancer	0.00015	0.00222	CbGeAlD
Erlotinib—SLCO2B1—lymph node—ovarian cancer	0.000149	0.0022	CbGeAlD
Erlotinib—CYP2C8—vagina—ovarian cancer	0.000148	0.00219	CbGeAlD
Erlotinib—ABL1—lymph node—ovarian cancer	0.000147	0.00218	CbGeAlD
Erlotinib—ABCG2—female gonad—ovarian cancer	0.000145	0.00214	CbGeAlD
Erlotinib—ABCG2—vagina—ovarian cancer	0.000144	0.00213	CbGeAlD
Erlotinib—CYP1A1—female gonad—ovarian cancer	0.000137	0.00203	CbGeAlD
Erlotinib—CYP1A1—vagina—ovarian cancer	0.000136	0.00202	CbGeAlD
Erlotinib—ALB—lymph node—ovarian cancer	0.000136	0.00201	CbGeAlD
Erlotinib—ABCB1—myometrium—ovarian cancer	0.000134	0.00199	CbGeAlD
Erlotinib—CYP3A5—female gonad—ovarian cancer	0.000134	0.00199	CbGeAlD
Erlotinib—CYP3A5—vagina—ovarian cancer	0.000133	0.00197	CbGeAlD
Erlotinib—CYP2C8—testis—ovarian cancer	0.000132	0.00195	CbGeAlD
Erlotinib—ABCB1—embryo—ovarian cancer	0.000129	0.00191	CbGeAlD
Erlotinib—ABCG2—testis—ovarian cancer	0.000128	0.0019	CbGeAlD
Erlotinib—CYP1B1—lymph node—ovarian cancer	0.000125	0.00185	CbGeAlD
Erlotinib—CYP3A4—female reproductive system—ovarian cancer	0.000111	0.00164	CbGeAlD
Erlotinib—CYP2D6—female reproductive system—ovarian cancer	0.000109	0.00161	CbGeAlD
Erlotinib—ABCB1—epithelium—ovarian cancer	0.000105	0.00156	CbGeAlD
Erlotinib—ABCB1—uterine cervix—ovarian cancer	0.000105	0.00155	CbGeAlD
Erlotinib—ABCB1—decidua—ovarian cancer	9.96e-05	0.00148	CbGeAlD
Erlotinib—CYP2D6—female gonad—ovarian cancer	9.91e-05	0.00147	CbGeAlD
Erlotinib—Dizziness—Topotecan—ovarian cancer	9.47e-05	0.000889	CcSEcCtD
Erlotinib—ABCB1—endometrium—ovarian cancer	9.46e-05	0.0014	CbGeAlD
Erlotinib—Renal impairment—Doxorubicin—ovarian cancer	9.32e-05	0.000875	CcSEcCtD
Erlotinib—Erythema multiforme—Docetaxel—ovarian cancer	9.3e-05	0.000873	CcSEcCtD
Erlotinib—ABCG2—lymph node—ovarian cancer	9.29e-05	0.00138	CbGeAlD
Erlotinib—Dermatitis bullous—Doxorubicin—ovarian cancer	9.28e-05	0.000871	CcSEcCtD
Erlotinib—Eye disorder—Docetaxel—ovarian cancer	9.19e-05	0.000863	CcSEcCtD
Erlotinib—Vomiting—Topotecan—ovarian cancer	9.11e-05	0.000855	CcSEcCtD
Erlotinib—Syncope—Paclitaxel—ovarian cancer	9.06e-05	0.00085	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—ovarian cancer	9.05e-05	0.00085	CcSEcCtD
Erlotinib—Rash—Topotecan—ovarian cancer	9.03e-05	0.000848	CcSEcCtD
Erlotinib—Dermatitis—Topotecan—ovarian cancer	9.02e-05	0.000847	CcSEcCtD
Erlotinib—Headache—Topotecan—ovarian cancer	8.97e-05	0.000842	CcSEcCtD
Erlotinib—Vomiting—Melphalan—ovarian cancer	8.92e-05	0.000837	CcSEcCtD
Erlotinib—Dehydration—Epirubicin—ovarian cancer	8.92e-05	0.000837	CcSEcCtD
Erlotinib—Loss of consciousness—Paclitaxel—ovarian cancer	8.88e-05	0.000833	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	8.87e-05	0.000833	CcSEcCtD
Erlotinib—Mediastinal disorder—Docetaxel—ovarian cancer	8.86e-05	0.000832	CcSEcCtD
Erlotinib—Rash—Melphalan—ovarian cancer	8.84e-05	0.00083	CcSEcCtD
Erlotinib—Dermatitis—Melphalan—ovarian cancer	8.84e-05	0.000829	CcSEcCtD
Erlotinib—Chills—Docetaxel—ovarian cancer	8.82e-05	0.000828	CcSEcCtD
Erlotinib—CYP1A1—lymph node—ovarian cancer	8.82e-05	0.00131	CbGeAlD
Erlotinib—Cough—Paclitaxel—ovarian cancer	8.81e-05	0.000827	CcSEcCtD
Erlotinib—Asthenia—Vinorelbine—ovarian cancer	8.79e-05	0.000825	CcSEcCtD
Erlotinib—Dry skin—Epirubicin—ovarian cancer	8.79e-05	0.000825	CcSEcCtD
Erlotinib—CYP2D6—testis—ovarian cancer	8.79e-05	0.0013	CbGeAlD
Erlotinib—Arrhythmia—Docetaxel—ovarian cancer	8.78e-05	0.000825	CcSEcCtD
Erlotinib—ABCB1—gonad—ovarian cancer	8.77e-05	0.0013	CbGeAlD
Erlotinib—Hypokalaemia—Epirubicin—ovarian cancer	8.73e-05	0.000819	CcSEcCtD
Erlotinib—ABCB1—uterus—ovarian cancer	8.71e-05	0.00129	CbGeAlD
Erlotinib—Alopecia—Docetaxel—ovarian cancer	8.69e-05	0.000816	CcSEcCtD
Erlotinib—Pruritus—Vinorelbine—ovarian cancer	8.67e-05	0.000814	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	8.63e-05	0.00081	CcSEcCtD
Erlotinib—Mental disorder—Docetaxel—ovarian cancer	8.62e-05	0.000809	CcSEcCtD
Erlotinib—Chest pain—Paclitaxel—ovarian cancer	8.6e-05	0.000807	CcSEcCtD
Erlotinib—Arthralgia—Paclitaxel—ovarian cancer	8.6e-05	0.000807	CcSEcCtD
Erlotinib—Myalgia—Paclitaxel—ovarian cancer	8.6e-05	0.000807	CcSEcCtD
Erlotinib—Anxiety—Paclitaxel—ovarian cancer	8.57e-05	0.000804	CcSEcCtD
Erlotinib—Erythema—Docetaxel—ovarian cancer	8.56e-05	0.000803	CcSEcCtD
Erlotinib—Malnutrition—Docetaxel—ovarian cancer	8.56e-05	0.000803	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	8.54e-05	0.000801	CcSEcCtD
Erlotinib—Nausea—Topotecan—ovarian cancer	8.51e-05	0.000799	CcSEcCtD
Erlotinib—Gastritis—Epirubicin—ovarian cancer	8.49e-05	0.000796	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	8.46e-05	0.000794	CcSEcCtD
Erlotinib—Diarrhoea—Vinorelbine—ovarian cancer	8.38e-05	0.000787	CcSEcCtD
Erlotinib—Nausea—Melphalan—ovarian cancer	8.33e-05	0.000782	CcSEcCtD
Erlotinib—Dysphagia—Epirubicin—ovarian cancer	8.29e-05	0.000778	CcSEcCtD
Erlotinib—Back pain—Docetaxel—ovarian cancer	8.28e-05	0.000777	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—ovarian cancer	8.25e-05	0.000774	CcSEcCtD
Erlotinib—Oedema—Paclitaxel—ovarian cancer	8.24e-05	0.000774	CcSEcCtD
Erlotinib—Infection—Paclitaxel—ovarian cancer	8.19e-05	0.000769	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—ovarian cancer	8.13e-05	0.000763	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—ovarian cancer	8.12e-05	0.000763	CcSEcCtD
Erlotinib—Shock—Paclitaxel—ovarian cancer	8.11e-05	0.000761	CcSEcCtD
Erlotinib—Dizziness—Vinorelbine—ovarian cancer	8.1e-05	0.000761	CcSEcCtD
Erlotinib—Nervous system disorder—Paclitaxel—ovarian cancer	8.08e-05	0.000759	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—ovarian cancer	8.07e-05	0.000758	CcSEcCtD
Erlotinib—Thrombocytopenia—Paclitaxel—ovarian cancer	8.07e-05	0.000758	CcSEcCtD
Erlotinib—Skin disorder—Paclitaxel—ovarian cancer	8.01e-05	0.000751	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	7.99e-05	0.00075	CcSEcCtD
Erlotinib—Anorexia—Paclitaxel—ovarian cancer	7.86e-05	0.000737	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—ovarian cancer	7.85e-05	0.000737	CcSEcCtD
Erlotinib—ABCB1—female reproductive system—ovarian cancer	7.83e-05	0.00116	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	7.82e-05	0.000734	CcSEcCtD
Erlotinib—Vomiting—Vinorelbine—ovarian cancer	7.79e-05	0.000731	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—ovarian cancer	7.75e-05	0.000727	CcSEcCtD
Erlotinib—Rash—Vinorelbine—ovarian cancer	7.73e-05	0.000725	CcSEcCtD
Erlotinib—Dermatitis—Vinorelbine—ovarian cancer	7.72e-05	0.000725	CcSEcCtD
Erlotinib—Headache—Vinorelbine—ovarian cancer	7.68e-05	0.000721	CcSEcCtD
Erlotinib—Syncope—Docetaxel—ovarian cancer	7.68e-05	0.000721	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—ovarian cancer	7.67e-05	0.00072	CcSEcCtD
Erlotinib—Loss of consciousness—Docetaxel—ovarian cancer	7.52e-05	0.000706	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—ovarian cancer	7.52e-05	0.000706	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	7.51e-05	0.000705	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—ovarian cancer	7.5e-05	0.000704	CcSEcCtD
Erlotinib—Cough—Docetaxel—ovarian cancer	7.47e-05	0.000701	CcSEcCtD
Erlotinib—Insomnia—Paclitaxel—ovarian cancer	7.46e-05	0.0007	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—ovarian cancer	7.43e-05	0.000698	CcSEcCtD
Erlotinib—ABCB1—bone marrow—ovarian cancer	7.39e-05	0.0011	CbGeAlD
Erlotinib—Infestation—Epirubicin—ovarian cancer	7.39e-05	0.000694	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—ovarian cancer	7.39e-05	0.000694	CcSEcCtD
Erlotinib—Dyspnoea—Paclitaxel—ovarian cancer	7.35e-05	0.00069	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	7.33e-05	0.000688	CcSEcCtD
Erlotinib—Arthralgia—Docetaxel—ovarian cancer	7.29e-05	0.000684	CcSEcCtD
Erlotinib—Chest pain—Docetaxel—ovarian cancer	7.29e-05	0.000684	CcSEcCtD
Erlotinib—Myalgia—Docetaxel—ovarian cancer	7.29e-05	0.000684	CcSEcCtD
Erlotinib—Nausea—Vinorelbine—ovarian cancer	7.28e-05	0.000683	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—ovarian cancer	7.26e-05	0.000682	CcSEcCtD
Erlotinib—Dyspepsia—Paclitaxel—ovarian cancer	7.26e-05	0.000681	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—ovarian cancer	7.24e-05	0.00068	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	7.24e-05	0.000679	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—ovarian cancer	7.2e-05	0.000676	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—ovarian cancer	7.18e-05	0.000674	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—ovarian cancer	7.17e-05	0.000673	CcSEcCtD
Erlotinib—Decreased appetite—Paclitaxel—ovarian cancer	7.17e-05	0.000673	CcSEcCtD
Erlotinib—ABCB1—female gonad—ovarian cancer	7.13e-05	0.00106	CbGeAlD
Erlotinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.12e-05	0.000668	CcSEcCtD
Erlotinib—Fatigue—Paclitaxel—ovarian cancer	7.11e-05	0.000667	CcSEcCtD
Erlotinib—ABCB1—vagina—ovarian cancer	7.08e-05	0.00105	CbGeAlD
Erlotinib—Pain—Paclitaxel—ovarian cancer	7.05e-05	0.000662	CcSEcCtD
Erlotinib—Constipation—Paclitaxel—ovarian cancer	7.05e-05	0.000662	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—ovarian cancer	6.99e-05	0.000656	CcSEcCtD
Erlotinib—Oedema—Docetaxel—ovarian cancer	6.99e-05	0.000656	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—ovarian cancer	6.97e-05	0.000654	CcSEcCtD
Erlotinib—Infection—Docetaxel—ovarian cancer	6.94e-05	0.000651	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—ovarian cancer	6.94e-05	0.000651	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—ovarian cancer	6.88e-05	0.000645	CcSEcCtD
Erlotinib—Shock—Docetaxel—ovarian cancer	6.87e-05	0.000645	CcSEcCtD
Erlotinib—Nervous system disorder—Docetaxel—ovarian cancer	6.85e-05	0.000643	CcSEcCtD
Erlotinib—Thrombocytopenia—Docetaxel—ovarian cancer	6.84e-05	0.000642	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—ovarian cancer	6.84e-05	0.000642	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—ovarian cancer	6.84e-05	0.000642	CcSEcCtD
Erlotinib—Skin disorder—Docetaxel—ovarian cancer	6.79e-05	0.000637	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	6.78e-05	0.000636	CcSEcCtD
Erlotinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	6.74e-05	0.000633	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—ovarian cancer	6.72e-05	0.000631	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	6.7e-05	0.000629	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—ovarian cancer	6.67e-05	0.000626	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—ovarian cancer	6.66e-05	0.000625	CcSEcCtD
Erlotinib—Anorexia—Docetaxel—ovarian cancer	6.66e-05	0.000625	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—ovarian cancer	6.65e-05	0.000624	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—ovarian cancer	6.63e-05	0.000623	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—ovarian cancer	6.63e-05	0.000623	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—ovarian cancer	6.55e-05	0.000615	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—ovarian cancer	6.52e-05	0.000612	CcSEcCtD
Erlotinib—Body temperature increased—Paclitaxel—ovarian cancer	6.52e-05	0.000612	CcSEcCtD
Erlotinib—Abdominal pain—Paclitaxel—ovarian cancer	6.52e-05	0.000612	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—ovarian cancer	6.5e-05	0.00061	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.47e-05	0.000607	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—ovarian cancer	6.45e-05	0.000605	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.37e-05	0.000597	CcSEcCtD
Erlotinib—ABCB1—testis—ovarian cancer	6.32e-05	0.000936	CbGeAlD
Erlotinib—Insomnia—Docetaxel—ovarian cancer	6.32e-05	0.000593	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—ovarian cancer	6.27e-05	0.000589	CcSEcCtD
Erlotinib—Dyspnoea—Docetaxel—ovarian cancer	6.23e-05	0.000585	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—ovarian cancer	6.2e-05	0.000582	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—ovarian cancer	6.17e-05	0.000579	CcSEcCtD
Erlotinib—Dyspepsia—Docetaxel—ovarian cancer	6.15e-05	0.000577	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—ovarian cancer	6.14e-05	0.000576	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—ovarian cancer	6.14e-05	0.000576	CcSEcCtD
Erlotinib—Decreased appetite—Docetaxel—ovarian cancer	6.07e-05	0.00057	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—ovarian cancer	6.06e-05	0.000569	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.03e-05	0.000566	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—ovarian cancer	6.03e-05	0.000566	CcSEcCtD
Erlotinib—Fatigue—Docetaxel—ovarian cancer	6.02e-05	0.000565	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—ovarian cancer	6.02e-05	0.000565	CcSEcCtD
Erlotinib—Mediastinal disorder—Epirubicin—ovarian cancer	5.98e-05	0.000561	CcSEcCtD
Erlotinib—Constipation—Docetaxel—ovarian cancer	5.97e-05	0.000561	CcSEcCtD
Erlotinib—Pain—Docetaxel—ovarian cancer	5.97e-05	0.000561	CcSEcCtD
Erlotinib—Chills—Epirubicin—ovarian cancer	5.95e-05	0.000559	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—ovarian cancer	5.93e-05	0.000556	CcSEcCtD
Erlotinib—Asthenia—Paclitaxel—ovarian cancer	5.91e-05	0.000555	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—ovarian cancer	5.86e-05	0.00055	CcSEcCtD
Erlotinib—Pruritus—Paclitaxel—ovarian cancer	5.83e-05	0.000547	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—ovarian cancer	5.81e-05	0.000545	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—ovarian cancer	5.8e-05	0.000545	CcSEcCtD
Erlotinib—Erythema—Epirubicin—ovarian cancer	5.77e-05	0.000542	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—ovarian cancer	5.77e-05	0.000542	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—ovarian cancer	5.74e-05	0.000538	CcSEcCtD
Erlotinib—Gastrointestinal pain—Docetaxel—ovarian cancer	5.71e-05	0.000536	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—ovarian cancer	5.69e-05	0.000534	CcSEcCtD
Erlotinib—Diarrhoea—Paclitaxel—ovarian cancer	5.64e-05	0.000529	CcSEcCtD
Erlotinib—Back pain—Epirubicin—ovarian cancer	5.59e-05	0.000524	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—ovarian cancer	5.53e-05	0.000519	CcSEcCtD
Erlotinib—Abdominal pain—Docetaxel—ovarian cancer	5.52e-05	0.000518	CcSEcCtD
Erlotinib—Body temperature increased—Docetaxel—ovarian cancer	5.52e-05	0.000518	CcSEcCtD
Erlotinib—Chills—Doxorubicin—ovarian cancer	5.51e-05	0.000517	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—ovarian cancer	5.48e-05	0.000515	CcSEcCtD
Erlotinib—Dizziness—Paclitaxel—ovarian cancer	5.45e-05	0.000512	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—ovarian cancer	5.42e-05	0.000509	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—ovarian cancer	5.38e-05	0.000505	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—ovarian cancer	5.34e-05	0.000501	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—ovarian cancer	5.34e-05	0.000501	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—ovarian cancer	5.26e-05	0.000494	CcSEcCtD
Erlotinib—Vomiting—Paclitaxel—ovarian cancer	5.24e-05	0.000492	CcSEcCtD
Erlotinib—Rash—Paclitaxel—ovarian cancer	5.2e-05	0.000488	CcSEcCtD
Erlotinib—Dermatitis—Paclitaxel—ovarian cancer	5.19e-05	0.000487	CcSEcCtD
Erlotinib—Syncope—Epirubicin—ovarian cancer	5.18e-05	0.000486	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—ovarian cancer	5.17e-05	0.000485	CcSEcCtD
Erlotinib—Headache—Paclitaxel—ovarian cancer	5.16e-05	0.000485	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—ovarian cancer	5.07e-05	0.000476	CcSEcCtD
Erlotinib—Cough—Epirubicin—ovarian cancer	5.04e-05	0.000473	CcSEcCtD
Erlotinib—Asthenia—Docetaxel—ovarian cancer	5.01e-05	0.00047	CcSEcCtD
Erlotinib—Pruritus—Docetaxel—ovarian cancer	4.94e-05	0.000464	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—ovarian cancer	4.92e-05	0.000461	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—ovarian cancer	4.92e-05	0.000461	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—ovarian cancer	4.92e-05	0.000461	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—ovarian cancer	4.9e-05	0.00046	CcSEcCtD
Erlotinib—Nausea—Paclitaxel—ovarian cancer	4.9e-05	0.00046	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.88e-05	0.000458	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—ovarian cancer	4.79e-05	0.00045	CcSEcCtD
Erlotinib—Diarrhoea—Docetaxel—ovarian cancer	4.78e-05	0.000449	CcSEcCtD
Erlotinib—Oedema—Epirubicin—ovarian cancer	4.71e-05	0.000442	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—ovarian cancer	4.7e-05	0.000441	CcSEcCtD
Erlotinib—Infection—Epirubicin—ovarian cancer	4.68e-05	0.000439	CcSEcCtD
Erlotinib—Cough—Doxorubicin—ovarian cancer	4.66e-05	0.000438	CcSEcCtD
Erlotinib—Shock—Epirubicin—ovarian cancer	4.64e-05	0.000435	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—ovarian cancer	4.62e-05	0.000434	CcSEcCtD
Erlotinib—Dizziness—Docetaxel—ovarian cancer	4.62e-05	0.000434	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—ovarian cancer	4.61e-05	0.000433	CcSEcCtD
Erlotinib—ABCB1—lymph node—ovarian cancer	4.58e-05	0.000679	CbGeAlD
Erlotinib—Skin disorder—Epirubicin—ovarian cancer	4.58e-05	0.00043	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—ovarian cancer	4.55e-05	0.000427	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—ovarian cancer	4.55e-05	0.000427	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—ovarian cancer	4.55e-05	0.000427	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—ovarian cancer	4.53e-05	0.000425	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.52e-05	0.000424	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—ovarian cancer	4.49e-05	0.000422	CcSEcCtD
Erlotinib—Vomiting—Docetaxel—ovarian cancer	4.44e-05	0.000417	CcSEcCtD
Erlotinib—Rash—Docetaxel—ovarian cancer	4.41e-05	0.000413	CcSEcCtD
Erlotinib—Dermatitis—Docetaxel—ovarian cancer	4.4e-05	0.000413	CcSEcCtD
Erlotinib—Headache—Docetaxel—ovarian cancer	4.38e-05	0.000411	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—ovarian cancer	4.36e-05	0.000409	CcSEcCtD
Erlotinib—Infection—Doxorubicin—ovarian cancer	4.33e-05	0.000407	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.29e-05	0.000403	CcSEcCtD
Erlotinib—Shock—Doxorubicin—ovarian cancer	4.29e-05	0.000403	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—ovarian cancer	4.28e-05	0.000401	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—ovarian cancer	4.27e-05	0.000401	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—ovarian cancer	4.26e-05	0.0004	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—ovarian cancer	4.24e-05	0.000398	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—ovarian cancer	4.2e-05	0.000394	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—ovarian cancer	4.16e-05	0.00039	CcSEcCtD
Erlotinib—Nausea—Docetaxel—ovarian cancer	4.15e-05	0.00039	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—ovarian cancer	4.15e-05	0.000389	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—ovarian cancer	4.1e-05	0.000384	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.07e-05	0.000382	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—ovarian cancer	4.06e-05	0.000381	CcSEcCtD
Erlotinib—Constipation—Epirubicin—ovarian cancer	4.03e-05	0.000378	CcSEcCtD
Erlotinib—Pain—Epirubicin—ovarian cancer	4.03e-05	0.000378	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.97e-05	0.000373	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—ovarian cancer	3.94e-05	0.00037	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—ovarian cancer	3.89e-05	0.000365	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—ovarian cancer	3.85e-05	0.000362	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—ovarian cancer	3.84e-05	0.00036	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—ovarian cancer	3.79e-05	0.000356	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.76e-05	0.000353	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—ovarian cancer	3.76e-05	0.000353	CcSEcCtD
Erlotinib—Pain—Doxorubicin—ovarian cancer	3.73e-05	0.00035	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—ovarian cancer	3.73e-05	0.00035	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—ovarian cancer	3.73e-05	0.00035	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—ovarian cancer	3.73e-05	0.00035	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.57e-05	0.000335	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—ovarian cancer	3.45e-05	0.000324	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—ovarian cancer	3.45e-05	0.000324	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—ovarian cancer	3.38e-05	0.000317	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—ovarian cancer	3.33e-05	0.000313	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—ovarian cancer	3.22e-05	0.000303	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—ovarian cancer	3.13e-05	0.000294	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—ovarian cancer	3.12e-05	0.000292	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—ovarian cancer	3.08e-05	0.00029	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—ovarian cancer	3e-05	0.000281	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—ovarian cancer	2.98e-05	0.00028	CcSEcCtD
Erlotinib—Rash—Epirubicin—ovarian cancer	2.97e-05	0.000279	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—ovarian cancer	2.97e-05	0.000279	CcSEcCtD
Erlotinib—Headache—Epirubicin—ovarian cancer	2.95e-05	0.000277	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—ovarian cancer	2.88e-05	0.000271	CcSEcCtD
Erlotinib—Nausea—Epirubicin—ovarian cancer	2.8e-05	0.000263	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—ovarian cancer	2.77e-05	0.00026	CcSEcCtD
Erlotinib—Rash—Doxorubicin—ovarian cancer	2.75e-05	0.000258	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—ovarian cancer	2.75e-05	0.000258	CcSEcCtD
Erlotinib—Headache—Doxorubicin—ovarian cancer	2.73e-05	0.000256	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—ovarian cancer	2.59e-05	0.000243	CcSEcCtD
Erlotinib—ALB—Metabolism—SLC2A1—ovarian cancer	3.34e-06	3.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—ovarian cancer	3.31e-06	3.81e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—ovarian cancer	3.3e-06	3.81e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—ovarian cancer	3.3e-06	3.8e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	3.29e-06	3.8e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.29e-06	3.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—ovarian cancer	3.28e-06	3.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—ovarian cancer	3.28e-06	3.78e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—ovarian cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—ovarian cancer	3.27e-06	3.77e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.27e-06	3.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MTOR—ovarian cancer	3.27e-06	3.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CB—ovarian cancer	3.27e-06	3.76e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1B1—ovarian cancer	3.22e-06	3.71e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—ovarian cancer	3.2e-06	3.69e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1B1—ovarian cancer	3.2e-06	3.69e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—ovarian cancer	3.19e-06	3.67e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CD—ovarian cancer	3.19e-06	3.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—ovarian cancer	3.16e-06	3.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—ovarian cancer	3.16e-06	3.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	3.11e-06	3.59e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.1e-06	3.57e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CG—ovarian cancer	3.08e-06	3.55e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—FASN—ovarian cancer	3.08e-06	3.55e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—ovarian cancer	3.07e-06	3.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—ovarian cancer	3.07e-06	3.53e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—ovarian cancer	3.06e-06	3.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—ovarian cancer	3.06e-06	3.52e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—ovarian cancer	3.04e-06	3.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—ovarian cancer	3.04e-06	3.5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—ovarian cancer	3.03e-06	3.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—ovarian cancer	3.03e-06	3.49e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—ovarian cancer	3.03e-06	3.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CAV1—ovarian cancer	3.03e-06	3.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTOR—ovarian cancer	3.02e-06	3.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CB—ovarian cancer	3.02e-06	3.48e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—YAP1—ovarian cancer	3.01e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—ovarian cancer	3e-06	3.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—ovarian cancer	3e-06	3.46e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.98e-06	3.44e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CD—ovarian cancer	2.97e-06	3.43e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—ovarian cancer	2.95e-06	3.4e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—ovarian cancer	2.95e-06	3.4e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—ovarian cancer	2.94e-06	3.39e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A1—ovarian cancer	2.92e-06	3.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ESR1—ovarian cancer	2.92e-06	3.36e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK3—ovarian cancer	2.91e-06	3.35e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—FASN—ovarian cancer	2.9e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—ovarian cancer	2.9e-06	3.34e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—ovarian cancer	2.89e-06	3.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6ST—ovarian cancer	2.87e-06	3.31e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	2.85e-06	3.29e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.85e-06	3.29e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—ovarian cancer	2.85e-06	3.28e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.84e-06	3.27e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—ovarian cancer	2.84e-06	3.27e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPP2R1A—ovarian cancer	2.84e-06	3.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—ovarian cancer	2.83e-06	3.26e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—ovarian cancer	2.83e-06	3.26e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.82e-06	3.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—ovarian cancer	2.82e-06	3.25e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK3—ovarian cancer	2.82e-06	3.25e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1B1—ovarian cancer	2.8e-06	3.23e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—ovarian cancer	2.8e-06	3.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—ovarian cancer	2.79e-06	3.22e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CB—ovarian cancer	2.78e-06	3.2e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—ovarian cancer	2.77e-06	3.19e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—ovarian cancer	2.77e-06	3.19e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—ovarian cancer	2.76e-06	3.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—ovarian cancer	2.76e-06	3.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—ovarian cancer	2.76e-06	3.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—ovarian cancer	2.76e-06	3.18e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.76e-06	3.17e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—ovarian cancer	2.72e-06	3.14e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CD—ovarian cancer	2.71e-06	3.12e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—ovarian cancer	2.69e-06	3.09e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—ovarian cancer	2.69e-06	3.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—ovarian cancer	2.68e-06	3.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—ovarian cancer	2.67e-06	3.08e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—ovarian cancer	2.65e-06	3.05e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—ovarian cancer	2.65e-06	3.05e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.64e-06	3.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—ovarian cancer	2.64e-06	3.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—ovarian cancer	2.63e-06	3.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.62e-06	3.02e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—ovarian cancer	2.61e-06	3.01e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—ovarian cancer	2.61e-06	3e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—ovarian cancer	2.61e-06	3e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—ovarian cancer	2.6e-06	3e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CB—ovarian cancer	2.59e-06	2.99e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—ovarian cancer	2.59e-06	2.98e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—ovarian cancer	2.54e-06	2.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—ovarian cancer	2.52e-06	2.91e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—ovarian cancer	2.52e-06	2.91e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—ovarian cancer	2.52e-06	2.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—ovarian cancer	2.51e-06	2.89e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	2.49e-06	2.86e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FASN—ovarian cancer	2.46e-06	2.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CD—ovarian cancer	2.42e-06	2.79e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CAV1—ovarian cancer	2.42e-06	2.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—ovarian cancer	2.42e-06	2.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—ovarian cancer	2.41e-06	2.78e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—ovarian cancer	2.4e-06	2.77e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—ovarian cancer	2.4e-06	2.77e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—ovarian cancer	2.4e-06	2.76e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—ovarian cancer	2.38e-06	2.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—ovarian cancer	2.37e-06	2.73e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.36e-06	2.72e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.34e-06	2.7e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—ovarian cancer	2.33e-06	2.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—ovarian cancer	2.33e-06	2.69e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—ovarian cancer	2.33e-06	2.69e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.33e-06	2.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—ovarian cancer	2.33e-06	2.68e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—ovarian cancer	2.32e-06	2.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—ovarian cancer	2.29e-06	2.64e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CAV1—ovarian cancer	2.29e-06	2.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.29e-06	2.63e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—ovarian cancer	2.27e-06	2.61e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—ovarian cancer	2.24e-06	2.58e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1B1—ovarian cancer	2.24e-06	2.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—ovarian cancer	2.23e-06	2.57e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—ovarian cancer	2.22e-06	2.56e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.21e-06	2.54e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—ovarian cancer	2.19e-06	2.52e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.18e-06	2.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	2.18e-06	2.51e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.18e-06	2.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—ovarian cancer	2.17e-06	2.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—ovarian cancer	2.17e-06	2.5e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—ovarian cancer	2.16e-06	2.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—ovarian cancer	2.14e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—ovarian cancer	2.14e-06	2.46e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	2.12e-06	2.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—ovarian cancer	2.12e-06	2.44e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—ovarian cancer	2.12e-06	2.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—ovarian cancer	2.11e-06	2.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	2.11e-06	2.43e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CAV1—ovarian cancer	2.1e-06	2.42e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CAV1—ovarian cancer	2.08e-06	2.4e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—ovarian cancer	2.08e-06	2.4e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—ovarian cancer	2.06e-06	2.38e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—ovarian cancer	2.04e-06	2.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	2.03e-06	2.34e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—ovarian cancer	2.02e-06	2.33e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	2.02e-06	2.32e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2e-06	2.31e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—ovarian cancer	2e-06	2.31e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.99e-06	2.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—ovarian cancer	1.99e-06	2.29e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.98e-06	2.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.98e-06	2.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.97e-06	2.28e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	1.96e-06	2.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—ovarian cancer	1.94e-06	2.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—ovarian cancer	1.94e-06	2.24e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.94e-06	2.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—ovarian cancer	1.93e-06	2.22e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.91e-06	2.2e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—ovarian cancer	1.9e-06	2.19e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—ovarian cancer	1.9e-06	2.19e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FASN—ovarian cancer	1.9e-06	2.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—ovarian cancer	1.89e-06	2.18e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.87e-06	2.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.87e-06	2.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.84e-06	2.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—ovarian cancer	1.84e-06	2.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—ovarian cancer	1.84e-06	2.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—ovarian cancer	1.84e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CD—ovarian cancer	1.83e-06	2.11e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.83e-06	2.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—ovarian cancer	1.83e-06	2.1e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—ovarian cancer	1.81e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.8e-06	2.08e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—ovarian cancer	1.79e-06	2.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	1.78e-06	2.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—ovarian cancer	1.76e-06	2.03e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.73e-06	1.99e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.72e-06	1.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—ovarian cancer	1.7e-06	1.96e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.69e-06	1.95e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.69e-06	1.95e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.68e-06	1.93e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CD—ovarian cancer	1.67e-06	1.92e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	1.65e-06	1.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—ovarian cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—ovarian cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—ovarian cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—ovarian cancer	1.63e-06	1.87e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CB—ovarian cancer	1.6e-06	1.84e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—ovarian cancer	1.58e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.57e-06	1.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	1.56e-06	1.8e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.53e-06	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—ovarian cancer	1.52e-06	1.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—ovarian cancer	1.5e-06	1.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	1.48e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.46e-06	1.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.46e-06	1.69e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—ovarian cancer	1.46e-06	1.68e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CAV1—ovarian cancer	1.46e-06	1.68e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CB—ovarian cancer	1.46e-06	1.68e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.44e-06	1.66e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.42e-06	1.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—ovarian cancer	1.4e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.4e-06	1.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.39e-06	1.61e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—ovarian cancer	1.38e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—ovarian cancer	1.38e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.38e-06	1.59e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.33e-06	1.53e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—ovarian cancer	1.29e-06	1.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	1.29e-06	1.48e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.27e-06	1.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—ovarian cancer	1.26e-06	1.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—ovarian cancer	1.26e-06	1.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—ovarian cancer	1.25e-06	1.44e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.2e-06	1.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—ovarian cancer	1.19e-06	1.37e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.17e-06	1.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.17e-06	1.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—ovarian cancer	1.14e-06	1.31e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.13e-06	1.3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—ovarian cancer	1.1e-06	1.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—ovarian cancer	1.05e-06	1.21e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—ovarian cancer	1.04e-06	1.2e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.03e-06	1.19e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.03e-06	1.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.02e-06	1.17e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—ovarian cancer	9.73e-07	1.12e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	9.01e-07	1.04e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	8.92e-07	1.03e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—ovarian cancer	8.87e-07	1.02e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—ovarian cancer	8.79e-07	1.01e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—ovarian cancer	8.41e-07	9.7e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—ovarian cancer	7.95e-07	9.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	7.86e-07	9.05e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	7.77e-07	8.96e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	7.32e-07	8.44e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—ovarian cancer	7.29e-07	8.4e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—ovarian cancer	7.25e-07	8.35e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—ovarian cancer	6.79e-07	7.82e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—ovarian cancer	6.35e-07	7.32e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—ovarian cancer	6.2e-07	7.15e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—ovarian cancer	5.98e-07	6.89e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—ovarian cancer	5.07e-07	5.84e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.79e-07	5.52e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—ovarian cancer	3.91e-07	4.51e-06	CbGpPWpGaD
